Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF -2.11%82 Return-on-Tangible-Asset is 13.85% as of Mar. 2026. GuruFocus rates CVALF with a GF Score™ of 82/100 and a GF Value™ of $1.55 (Fairly Valued). The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Covalon Technologies ranks better than 64.24% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Covalon Technologies's annualizedNet Income for the quarter that ended in Mar. 2026 was $3.19 Mil. Covalon Technologies's average total tangible assets for the quarter that ended in Mar. 2026 was $23.02 Mil. Therefore, Covalon Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 13.85%.
The historical rank and industry rank for Covalon Technologies's Return-on-Tangible-Asset or its related term are showing as below:
CVALF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -58.5 Med: -5.39 Max: 79.3
Current: 4.95
During the past 13 years, Covalon Technologies's highest Return-on-Tangible-Asset was 79.30%. The lowest was -58.50%. And the median was -5.39%.
CVALF's Return-on-Tangible-Asset is ranked better than 64.24% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs CVALF: 4.95
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Covalon Technologies Return-on-Tangible-Asset Related Terms
Covalon Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.85% mean?
Covalon Technologies (CVALF) has a Return-on-Tangible-Asset of 13.85% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Covalon Technologies and its competitors. According to the industry distribution chart, Covalon Technologies ranks #305 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is Covalon Technologies' Return-on-Tangible-Asset too high?
Covalon Technologies' current Return-on-Tangible-Asset is 13.85%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Covalon Technologies' value of 13.85% is 1456.2% above this industry median. Based on the distribution chart, Covalon Technologies ranks #305 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #305 out of 853 companies for Return-on-Tangible-Asset. This puts Covalon Technologies in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.89. Covalon Technologies' value of 13.85% is 1456.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Return-on-Tangible-Asset of 13.85% is 1456.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Return-on-Tangible-Asset is 13.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.55, compared to a current price of $1.67 — trading 8% above its estimated fair value. The current Return-on-Tangible-Asset is 13.85% and 1456.2% above the Medical Devices & Instruments industry median of 0.89. Covalon Technologies' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Return-on-Tangible-Asset is 13.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be overvalued.
The current stock price of $1.67 is trading 8% above its estimated GF Value™ of $1.55.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Return-on-Tangible-Asset: 13.85%
GF Value™: $1.55 vs. price of $1.67 (8% above fair value)
Industry Position: 1456.2% above the Medical Devices & Instruments median (#305 of 853)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
82GF Score
Get the complete analysis for CVALF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
